- Zacks•18 days ago
The availability of the AR-V7 serves as a further development to Genomic Health's (GHDX) recently launched Oncotype SEQ Liquid Select, a next-generation, liquid biopsy test.
- The Wall Street Journal•20 days ago
Genomic Health has struck a deal to commercialize a new blood test that can help advanced prostate cancer patients decide whether to try costly new-generation drugs or rely on much cheaper traditional ...
Genomic Health Inc.NasdaqGS
After hours: 28.730.00 (0.00%) as of 4:56 PM EDT
|Ask||31.12 x 2000|
|52wk Range||20.05 - 35.79|
|Day's Range||28.09 - 28.88|
|Avg Vol (3m)||187,542|
As of 4:00 PM EDT. Market closed.